Abbott India Limited (ABBOTINDIA)

Name: Abbott India Limited（ABBOTINDIA）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-09-20

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products.

关键数据

市值: ₹579 billion
收入（截至 2026-03-31 财年）: ₹69.3B
净利润: ₹15.5B
毛利率: 46.5%
净利率: 22.4%

查看交互式图表与完整报表 →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31
总收入	₹69.3B	₹64.1B	₹58.5B	₹53.5B
毛利	₹32.2B	₹29.0B	₹26.1B	₹23.6B
营业利润（EBIT）	₹18.2B	₹16.4B	₹14.1B	₹11.5B
净利	₹15.5B	₹14.1B	₹12.0B	₹9.5B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 ABBOTINDIA 交互式查看器。 /companies/us/ABBOTINDIA

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.